Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/08/591   
Active ingredient: 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole
Indication: Treatment of Duchenne muscular dystrophy
Sponsor: Summit (Oxford) Limited
136a Eastern Avenue, Milton Park, Abingdon, Oxforshire OX14 4SB, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
09/12/2008 Orphan designation EMEA/OD/065/08 (2008)8166 of 04/12/2008
26/05/2009 Transfer of orphan designation EMEA/OD/065/08/T/01 (2009)4112 of 20/05/2009
11/03/2011 Transfer of orphan designation EMEA/OD/065/08/T/02 (2011)1686 of 09/03/2011
28/01/2014 Change of name and/or address of sponsor
19/05/2017 Change of name and/or address of sponsor